We are live on ! Find out more
STOK icon

Stoke Therapeutics
STOK

103 hedge funds and large institutions have $732M invested in Stoke Therapeutics in 2024 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 35 increasing their positions, 27 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

256% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 9

187% more capital invested

Capital invested by funds: $255M → $732M (+$477M)

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

30% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 27

27% more funds holding

Funds holding: 81 → 103 (+22)

8.74% more ownership

Funds ownership: 108.41% → 117.15% (+8.7%)

16% less call options, than puts

Call options by funds: $1.9M | Put options by funds: $2.27M

Holders
103
Holders Change
+22
Holders Change %
+27.16%
% of All Funds
1.48%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.07%
New
32
Increased
35
Reduced
27
Closed
9
Calls
$1.9M
Puts
$2.27M
Net Calls
-$373K
Net Calls Change
-$374K

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$14.8M
2
BlackRock
BlackRock
New York
+$10.9M
3
BBA
Baker Bros. Advisors
New York
+$8.11M
4
Franklin Resources
Franklin Resources
California
+$6.41M
5
LCM
Lynx1 Capital Management
Puerto Rico
+$4.48M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$16.5M
2
GIM
Granahan Investment Management
Massachusetts
-$4.01M
3
CAM
Cormorant Asset Management
Massachusetts
-$4M
4
CAC
Cowen and Company
New York
-$2.16M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$728K
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$2.62M +$309K +51,049 +36%
Marshall Wace
27
Marshall Wace
United Kingdom
$2.41M +$1.08M +178,586 New
DCM
28
DAFNA Capital Management
California
$1.96M +$878K +145,000 New
Wellington Management Group
29
Wellington Management Group
Massachusetts
$1.94M +$868K +143,351 New
Point72 Asset Management
30
Point72 Asset Management
Connecticut
$1.92M +$863K +142,458 New
PAI
31
Palo Alto Investors
California
$1.7M +$763K +125,861 New
N
32
Nuveen
North Carolina
$1.62M +$342K +56,480 +89%
WP
33
Woodline Partners
California
$1.44M +$303K +50,000 +88%
LCM
34
Laurion Capital Management
New York
$1.35M +$606K +100,000 New
MS
35
Maven Securities
Jersey
$1.35M +$606K +100,000 New
GCP
36
GSA Capital Partners
United Kingdom
$1.32M -$27.9K -4,599 -5%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$1.21M -$51K -8,424 -9%
GGHC
38
Gilder Gagnon Howe & Co
New York
$1.21M +$167K +27,535 +44%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$1.07M +$353K +58,242 +274%
FPCP
40
Fort Point Capital Partners
California
$1.02M – – –
MIM
41
Monashee Investment Management
Massachusetts
$912K +$409K +67,584 New
Los Angeles Capital Management
42
Los Angeles Capital Management
California
$840K – – –
Mirae Asset Global Investments
43
Mirae Asset Global Investments
South Korea
$728K +$549K +90,663 New
Squarepoint
44
Squarepoint
New York
$690K +$194K +32,001 +168%
LP
45
LMR Partners
United Kingdom
$675K +$303K +50,000 New
Norges Bank
46
Norges Bank
Norway
$675K +$303K +50,000 New
State of Wisconsin Investment Board
47
State of Wisconsin Investment Board
Wisconsin
$651K -$233K -38,400 -44%
Jacobs Levy Equity Management
48
Jacobs Levy Equity Management
New Jersey
$647K -$728K -120,116 -71%
Millennium Management
49
Millennium Management
New York
$621K +$134K +22,070 +92%
EI
50
EAM Investors
California
$619K +$278K +45,845 New
1
2
3 4 5

STOK Hedge Fund Activity: Q1 2024 in Review

103 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q1 2024, worth a combined $732M — up 187% from $255M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new STOK positions and 9 closed out — a net gain of 23 holders — while 35 added to existing stakes and 27 trimmed.

The largest buyer was Redmile Group, adding an estimated $14.8M. The largest seller was Morgan Stanley, cutting an estimated $16.5M.

  • 103 institutional investors held Stoke Therapeutics (STOK) as of Q1 2024, up from 81 in Q4 2023.
  • Funds reported $732M of Stoke Therapeutics stock for Q1 2024, up 187% quarter-over-quarter.
  • 32 funds opened new Stoke Therapeutics positions in Q1 2024 and 9 closed out, a net change of +23 holders.
  • The largest Stoke Therapeutics buyer in Q1 2024 was Redmile Group, an estimated $14.8M added.
  • The largest Stoke Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $16.5M sold.

Based on aggregated 13F filings for Q1 2024.